FR2931480B1 - Analogues synthetiques de phosphatidyl-myo-inositol mannosides pourvus d'une active inhibitrice de la reponse inflammatoire - Google Patents

Analogues synthetiques de phosphatidyl-myo-inositol mannosides pourvus d'une active inhibitrice de la reponse inflammatoire

Info

Publication number
FR2931480B1
FR2931480B1 FR0853357A FR0853357A FR2931480B1 FR 2931480 B1 FR2931480 B1 FR 2931480B1 FR 0853357 A FR0853357 A FR 0853357A FR 0853357 A FR0853357 A FR 0853357A FR 2931480 B1 FR2931480 B1 FR 2931480B1
Authority
FR
France
Prior art keywords
myo
phosphatidyl
inflammatory response
synthetic analogues
active inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0853357A
Other languages
English (en)
Other versions
FR2931480A1 (fr
Inventor
Ryffel Valerie Quesniaux
Olivier Martin
Sophie Front
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0853357A priority Critical patent/FR2931480B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to US12/994,059 priority patent/US8846880B2/en
Priority to JP2011510020A priority patent/JP5535202B2/ja
Priority to PCT/FR2009/000595 priority patent/WO2009153434A2/fr
Priority to CA2724767A priority patent/CA2724767A1/fr
Priority to EP09765996.5A priority patent/EP2280986B1/fr
Priority to ES09765996T priority patent/ES2436267T3/es
Publication of FR2931480A1 publication Critical patent/FR2931480A1/fr
Application granted granted Critical
Publication of FR2931480B1 publication Critical patent/FR2931480B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
FR0853357A 2008-05-23 2008-05-23 Analogues synthetiques de phosphatidyl-myo-inositol mannosides pourvus d'une active inhibitrice de la reponse inflammatoire Active FR2931480B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0853357A FR2931480B1 (fr) 2008-05-23 2008-05-23 Analogues synthetiques de phosphatidyl-myo-inositol mannosides pourvus d'une active inhibitrice de la reponse inflammatoire
JP2011510020A JP5535202B2 (ja) 2008-05-23 2009-05-20 炎症応答に対する抑制活性を有する、ホスファチジルーミオーイノシトールマンノシドの合成類似体
PCT/FR2009/000595 WO2009153434A2 (fr) 2008-05-23 2009-05-20 Analogues synthetiques des phosphatidyl-myo-inositol mannosides pourvus d'une activite inhibitrice de la reponse inflammatoire.
CA2724767A CA2724767A1 (fr) 2008-05-23 2009-05-20 Analogues synthetiques des phosphatidyl-myo-inositol mannosides pourvus d'une activite inhibitrice de la reponse inflammatoire
US12/994,059 US8846880B2 (en) 2008-05-23 2009-05-20 Synthetic analogues of phosphatidyl-myo-inositol mannosides with an inhibitory activity of the inflammatory response
EP09765996.5A EP2280986B1 (fr) 2008-05-23 2009-05-20 Analogues synthetiques des phosphatidyl-myo-inositol mannosides pourvus d'une activite inhibitrice de la reponse inflammatoire.
ES09765996T ES2436267T3 (es) 2008-05-23 2009-05-20 Análogos sintéticos manósidos fosfatidil-mio-inositol con actividad inhibidora de la respuesta inflamatoria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0853357A FR2931480B1 (fr) 2008-05-23 2008-05-23 Analogues synthetiques de phosphatidyl-myo-inositol mannosides pourvus d'une active inhibitrice de la reponse inflammatoire

Publications (2)

Publication Number Publication Date
FR2931480A1 FR2931480A1 (fr) 2009-11-27
FR2931480B1 true FR2931480B1 (fr) 2016-04-01

Family

ID=40289351

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0853357A Active FR2931480B1 (fr) 2008-05-23 2008-05-23 Analogues synthetiques de phosphatidyl-myo-inositol mannosides pourvus d'une active inhibitrice de la reponse inflammatoire

Country Status (7)

Country Link
US (1) US8846880B2 (fr)
EP (1) EP2280986B1 (fr)
JP (1) JP5535202B2 (fr)
CA (1) CA2724767A1 (fr)
ES (1) ES2436267T3 (fr)
FR (1) FR2931480B1 (fr)
WO (1) WO2009153434A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20120473A1 (it) 2012-10-04 2014-04-05 Consiglio Nazionale Ricerche Use of glycerophosphoinositols for the treatment of septic shock
CN113825544A (zh) * 2019-05-13 2021-12-21 昭和电工株式会社 癌细胞增殖抑制剂及癌细胞增殖抑制用组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2596651B1 (fr) * 1986-04-08 1989-11-10 Centre Nat Rech Scient Nouveaux liposomes a base de phosphatidylinositolmannosides, et compositions pharmaceutiques les contenant
CA2440744C (fr) * 2001-03-15 2009-12-08 Seikagaku Corporation Agent de regulation d'expression d'il-12
ES2347421T3 (es) * 2001-08-03 2010-10-29 National Research Council Of Canada Liposomas preparados a partir de lipidos extraibles de mycobacterium.
US7989602B2 (en) * 2003-11-18 2011-08-02 The Malaghan Institute Of Medical Research Synthetic molecules having immune activity
FR2908658B1 (fr) * 2006-11-20 2011-11-11 Centre Nat Rech Scient Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12
NZ552205A (en) * 2006-12-20 2009-10-30 Ind Res Ltd Phosphatidylinositol mannosides and analogues thereof

Also Published As

Publication number Publication date
EP2280986A2 (fr) 2011-02-09
JP5535202B2 (ja) 2014-07-02
US8846880B2 (en) 2014-09-30
CA2724767A1 (fr) 2009-12-23
JP2011520946A (ja) 2011-07-21
WO2009153434A3 (fr) 2010-05-14
ES2436267T3 (es) 2013-12-30
EP2280986B1 (fr) 2013-07-10
US20110224162A1 (en) 2011-09-15
WO2009153434A8 (fr) 2011-02-24
FR2931480A1 (fr) 2009-11-27
WO2009153434A2 (fr) 2009-12-23

Similar Documents

Publication Publication Date Title
BRPI0820928A2 (pt) Fabricação de elementos com baixa fricção
BRPI0917625A2 (pt) substratos que fornecem liberações multiplas de agentes ativos
BRPI0818874A2 (pt) Liberação de agentes ativos
DK2180182T3 (da) Aktiv cirkulationsstyring af aerodynamiske strukturer
CR20140154A (es) Compuestos para inhibir la progresión mitotica
DK2361256T3 (da) Cyclohexenyl-nukleinsyreanaloger
BRPI0922464A2 (pt) Combinações de compostos ativos
BRPI0817524A2 (pt) liberação prolongada de análogos de compstatina provenientes de géis
BRPI0718875A2 (pt) Cobertura com níveis reduzidos de ácido graxo saturado
BRPI0921299A2 (pt) Compostos de benzamida adamantila
FI20075600A0 (fi) Komponentin eliniän määritys
BR112013006165A2 (pt) composição de revestimento à base d'água
BRPI0820831A2 (pt) Combinações de composto ativo
ATE515503T1 (de) Antiparasitische benzofuranmittel
DK2173197T3 (da) Fremgangsmåde
ITRE20080006A1 (it) '' lavapavimenti ''
IT1393723B1 (it) Struttura di casseratura per l'esecuzione di solai e simili
FR2931480B1 (fr) Analogues synthetiques de phosphatidyl-myo-inositol mannosides pourvus d'une active inhibitrice de la reponse inflammatoire
IT1391610B1 (it) Lavapavimenti
FR2916759B1 (fr) Peptide rumc presentant une activite antimicrobienne
BRPI0808927A2 (pt) Formas sólidas de microbiocida
DK2240433T3 (da) Polymorfe former af oseltamivir-phosphat
FR2935219B1 (fr) Tondeuse du type autoporte
FR2929850B1 (fr) Inhibiteurs de l'enzyme tyrosinage
FR2936845B1 (fr) Cage d'ecrou

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10